Document:

EX-10.13

 Exhibit 10.13 

Certain identified information has been excluded from the exhibit because it is both (i) not 

material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. 

Double asterisks denote omissions. 

EXCLUSIVE LICENSE AGREEMENT 
 THIS
EXCLUSIVE LICENSE AGREEMENT (“AGREEMENT”) is made and entered into the date of last signature (“EFFECTIVE DATE”), by and between THE CURATORS OF THE UNIVERSITY OF MISSOURI, a public corporation of the State of Missouri
(“UNIVERSITY”) and DECIBEL THERAPEUTICS, INC., a Delaware for-profit corporation having offices at 1325 Boylston Street, Suite 500, Boston, MA 02215 (“LICENSEE”). UNIVERSITY and LICENSEE
may sometimes be referred to herein as a “PARTY” or “PARTIES” as the case may be. 
 WHEREAS, UNIVERSITY has an ownership interest in
certain PATENT RIGHTS as defined herein related to UM Disclosure No. [**]; and 
 WHEREAS, the PATENT RIGHTS were developed under a research program
sponsored by National Institutes of Health. Therefore, this AGREEMENT is subject to the terms and conditions of the Bayh-Dole Act, Public Law 96-517 and 98-620 as
amended; and 
 WHEREAS, LICENSEE is desirous of obtaining a license to practice the PATENT RIGHTS under the terms and conditions of this AGREEMENT; and

 WHEREAS, UNIVERSITY is desirous of granting such a license to LICENSEE in accordance with the terms and conditions of this AGREEMENT. 

NOW, THEREFORE, in consideration of the foregoing premises and the covenants, representations and warranties contained herein, the PARTIES agree as follows:

 Article I. DEFINITIONS 

Section 1.01 “AFFILIATE” means any business entity more than fifty percent (50%) owned by LICENSEE, any business entity which owns more than
fifty percent (50%) of LICENSEE, or any business entity that is more than fifty percent (50%) owned by a business entity that owns more than fifty percent (50%) of LICENSEE. 

Section 1.02 “IMPROVEMENTS” shall mean any modification, enhancement, or improvement to an invention described in the PATENT RIGHTS, where such
modification, enhancement, or improvement is owned by, licensed to, or otherwise controlled by LICENSEE that (a) would be infringed, either directly or indirectly, by the practice of an invention claimed in the PATENT RIGHTS or (b) if not
for the license granted under this AGREEMENT, would infringe, either directly or indirectly, one or more claims of the PATENT RIGHTS. 
 Section 1.03
“LICENSED FIELD” means each of the following business areas: 
 (a) Therapy for hearing loss caused by mutations in the otoferlin
gene (“OTOFERLIN LICENSED SUBFIELD”); and 
 (b) Therapy for hearing loss caused by mutations in the [**] gene (“[**] LICENSED
SUBFIELD”). 

 Section 1.04 “LICENSED PRODUCT” means any (a) product, apparatus, kit, composition, or
component thereof (i) whose use, SALE, offer for SALE, or importation of which is covered, in whole or in part, by any issued, unexpired, or pending claim contained in the PATENT RIGHTS or (ii) which is made by any method, procedure,
process, or step which is covered, in whole or in part, by any issued, unexpired, or pending claim contained in the PATENT RIGHTS; or (b) any method, procedure, process, or step which is covered, in whole or in part, by any issued, unexpired,
or pending claim contained in the PATENT RIGHTS. 
 Section 1.05 “LICENSED TERRITORY” means the United States of America. 

Section 1.06 “NET SALES” means the amount billed or invoiced for the SALE of LICENSED PRODUCTS, less: 

 

	 	(a)	 Normal and customary trade, quantity and cash discounts actually given, chargebacks and any other allowances;

  

	 	(b)	 Credits and allowances, including for rejections or returns of any LICENSED PRODUCT; 

 

	 	(c)	 Amounts repaid or credited by reason of rejection, defects, recalls, or returns or because of chargebacks,
refunds, rebates or retroactive price reductions; 

  

	 	(d)	 Discounts mandated by, or granted to meet the requirements of law, including required chargebacks and
retroactive price reductions; 

  

	 	(e)	 Bad debts and uncollectible receivables; 

 

	 	(f)	 Charges for transportation or delivery to be paid by or on behalf of LICENSEE’s customer, to the extent
such charges are separately stated on purchase orders, invoices or other documents of SALE; and 

  

	 	(g)	 Sales, tariff duties, turnover, excise, value added, and/or use taxes directly imposed and with reference to
particular SALES. 

 In calculating NET SALES, no deductions shall be made for commissions paid to individuals whether they are with
independent sales agencies or regularly employed by LICENSEE and on its payroll, or for cost of collections. In the event LICENSEE SELLS a LICENSED PRODUCT to a third party in a bona fide arm’s length transaction, for consideration, in whole or
in part, other than cash, then the NET SALES price for such LICENSED PRODUCT shall be deemed to be the standard invoice price then being invoiced by LICENSEE in an arm’s length transaction with similar entities and in the absence of such
standard invoice price, then the reasonable fair market value of the LICENSED PRODUCT. For the purposes of calculating NET SALES, LICENSEE’s SALES to a SUBLICENSEE or to an AFFILIATE under this AGREEMENT for end use (but not resale) by the
SUBLICENSEE or the AFFILIATE shall be treated as SALES by LICENSEE at the greater of the (i) billed/invoiced price of LICENSEE the SUBLICENSEE or AFFILIATE or (ii) the billed/invoiced price that LICENSEE would have charged a third party in
a bona fide arm’s length transaction. For the purposes of calculating NET SALES, LICENSEE’s SALES to a SUBLICENSEE or to an AFFILIATE under this AGREEMENT for resale to end users by the SUBLICENSEE or an AFFILIATE shall be treated as SALES
at the billed/invoiced price to the end users of SUBLICENSEE or AFFILIATE. 

  
 2 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 1.07 “NON-COMMERCIAL RESEARCH PURPOSES” means
research, teaching, educational, or academic purposes which are undertaken at UNIVERSITY or at a non-profit, academic, educational, or governmental institution. Without limiting the foregoing, NON-COMMERCIAL RESEARCH PURPOSES includes research (including sponsored research) that leads, or may lead, to patentable or unpatentable inventions that may be licensed or otherwise transferred, either directly or
indirectly, to third parties. 
 Section 1.08 “PATENT EXPENSES” means all
out-of-pocket expenses, costs, and attorneys’ fees UNIVERSITY has incurred or will incur for the preparation, filing, prosecution and maintenance of the PATENT
RIGHTS, including but not limited to interferences, derivation proceedings, re-examinations, reissues, oppositions, supplemental examinations, inter partes reviews, and post grant reviews. 

Section 1.09 “PATENT RIGHTS” means UNIVERSITY’S rights in any of the following: (a) the United States patent No. [**] (“PATENT
APPLICATION”); and (b) any provisional, non-provisional, divisional, continuation (but not continuations-in-part),
extension, renewal, re-examination, reissue, substitute, supplementary protection certificate, utility model, or similar legal protection claiming priority to or from the PATENT APPLICATION. All of the
foregoing will be automatically incorporated in and added to this AGREEMENT and shall periodically be added to Appendix A attached to this AGREEMENT and made part thereof. 

Section 1.10 “ROYALTY PERIOD(S)” means the three-month periods ending on March 31, June 30, September 30, and December 31. 

Section 1.11 “SALE”, “SELL”, or “SOLD” means the sale, use, transfer, distribution or disposition of a LICENSED PRODUCT for
value to a third party. 
 Section 1.12 “SUBLICENSEE” means any person or entity to whom LICENSEE transfers any right or interest granted to
LICENSEE by UNIVERSITY under this AGREEMENT and who is not an AFFILIATE. 
 Article II. GRANT 

Section 2.01 Grant. Subject to the terms and conditions of this AGREEMENT, UNIVERSITY hereby grants to LICENSEE and LICENSEE accepts a
royalty-bearing, exclusive license under the PATENT RIGHTS to make, have made, use, SELL, have SOLD, import, distribute, or otherwise transfer LICENSED PRODUCTS within the LICENSED TERRITORY for use within LICENSED FIELD for a term as set forth in
Section 10.01 unless this AGREEMENT shall be sooner terminated according to the terms hereof. For the avoidance of doubt, this grant is subject to the rights retained by UNIVERSITY in Section 2.04, UNIVERSITY’s publication rights in
Section 2.07, and any rights of the GOVERNMENT as set forth in Section 2.08. 

  
 3 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 2.02 Affiliates. The license granted to LICENSEE may be extended to an AFFILIATE of
LICENSEE as well, on the condition that UNIVERSITY first receives written notice, signed on behalf of both LICENSEE and the AFFILIATE: (a) stating that the AFFILIATE intends to exercise such rights, and (b) agreeing that the AFFILIATE and
LICENSEE shall be jointly and severally liable for all obligations to UNIVERSITY under this AGREEMENT arising from the activities of that AFFILIATE. The activities or omissions of the AFFILIATE under this AGREEMENT shall then be deemed to be the
activities of LICENSEE. The rights of an AFFILIATE under this AGREEMENT shall terminate if LICENSEE’s rights under this AGREEMENT terminate. An AFFILIATE may not assign or otherwise transfer any rights under this AGREEMENT, without the prior
written consent of UNIVERSITY, which consent shall not be unreasonably withheld. If an entity ceases to be an AFFILIATE, then all of such entity’s rights under this AGREEMENT shall terminate. 

Section 2.03 Sublicenses. The license granted in Section 2.01 above shall include the right to grant written sublicenses through multiple
tiers, subject to UNIVERSITY’s prior written approval [**], UNIVERSITY will consider, among other things, whether the provisions of the proposed sublicense are consistent with and similar to those required of LICENSEE by this AGREEMENT. All
sublicenses must comply with the following: 
  

	 	(a)	 LICENSEE shall deliver to UNIVERSITY a true and correct copy of each fully executed sublicense granted by
LICENSEE, and any modification or termination thereof, within [**] after execution, modification, or termination. 

  

	 	(b)	 LICENSEE shall deliver to UNIVERSITY copies of all reports due to LICENSEE from SUBLICENSEE within [**] receipt
of such reports by LICENSEE. 

  

	 	(c)	 LICENSEE shall, at such reasonable times as UNIVERSITY directs and at UNIVERSITY’s reasonable request, but
in any event not more than [**], permit the inspection of SUBLICENSEE’s records by UNIVERSITY’s auditors or an independent certified public accountant selected by UNIVERSITY under the terms of Section 4.05. 

 

	 	(d)	 No sublicense shall relieve LICENSEE of its representations, warranties, or obligations under this AGREEMENT.
LICENSEE shall be responsible to UNIVERSITY for the performance of its SUBLICENSEES under each sublicense agreement granting rights to any PATENT RIGHTS. LICENSEE hereby guarantees each SUBLICENSEE’s compliance with the terms and conditions of
the license granted by UNIVERSITY under this AGREEMENT, including but not limited to the payment of all fees and royalties due under this AGREEMENT. 

  

	 	(e)	 Any sublicense granted by LICENSEE to a SUBLICENSEE shall incorporate all of the representations, warranties,
terms, conditions, and obligations of this AGREEMENT, which shall be binding upon each SUBLICENSEE as if such SUBLICENSEE were a party to this AGREEMENT. LICENSEE shall require that any sublicense agreement: 

 

	 	(i)	 be consistent with the terms, conditions, covenants, warranties, representations, limitations, obligations, and
duties of LICENSEE under this AGREEMENT; and 

  
 4 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(ii)	 contain express provisions under which the SUBLICENSEE expressly accepts duties and obligations at least
equivalent to those accepted by the LICENSEE in the following sections of this AGREEMENT: Section 2.04 (reserved rights), Section 2.05 (license to University), Section 2.07 (publication), Section 2.08 (governmental rights),
Section 3.07 (challenge to patent rights), Section 4.03 (reporting), Section 4.05 (records), Section 6.01 (indemnity), Section 6.02 (insurance), Section 6.03 (disclaimer of warranties), Section 6.04 (damages
exclusion/ limitation of remedies), Section 6.06 (sublicenses) Section 7.04 (entity status), Section 10.05 (assignment of sublicenses), Section 11.01 (marking), Section 11.02 (compliance with laws / export controls),
Section 11.03 (university name), and Section 11.11 (severability). 

  

	 	(f)	 Without UNIVERSITY prior written consent, if any sublicense agreement granting any rights to the PATENT RIGHTS
does not comport with above requirements in this Section 2.03(e), then that agreement shall be invalid, unenforceable, and void. Notwithstanding any such UNIVERSITY prior written consent, in the event of any inconsistency between this AGREEMENT
and any sublicense agreement, the terms and conditions of this AGREEMENT shall prevail. 

  

	 	(g)	 Upon any termination of this AGREEMENT, all SUBLICENSEE’s rights shall also terminate except as set forth
in Section 10.05 (assignment of sublicenses). 

 Section 2.04 Reserved Rights. UNIVERSITY reserves the right to make, use
or otherwise practice the PATENT RIGHTS for NON-COMMERCIAL RESEARCH PURPOSES and to grant nonexclusive licenses to non-profit, academic, educational, or governmental
institutions a royalty-free right to make, use or otherwise practice the PATENT RIGHTS for NON-COMMERCIAL RESEARCH PURPOSES. UNIVERSITY also reserves the right to transfer tangible research materials and
intangible materials incorporating the PATENT RIGHTS to other non-profit, academic, educational, or governmental institutions for such NON-COMMERCIAL RESEARCH PURPOSES.
LICENSEE agrees that, notwithstanding any other provision of this AGREEMENT, that LICENSEE has no right to enforce the PATENT RIGHTS against UNIVERSITY or any non-profit, academic, educational, or governmental
institution with respect to such use or practice for NON-COMMERCIAL RESEARCH PURPOSES.
 Section 2.05
License to University. LICENSEE hereby grants, and shall require its SUBLICENSEE(S) to grant to UNIVERSITY, a nonexclusive, royalty-free, irrevocable, paid-up license, with the right to grant
sublicenses to non-profit, academic, educational, or government institutions working in collaboration with UNIVERSITY, to practice and use IMPROVEMENTS for
NON-COMMERCIAL RESEARCH PURPOSES only. 
 Section 2.06 License Scope. The license granted herein shall
not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology not specifically set forth in PATENT RIGHTS. LICENSEE shall at all times refrain from making, using, SELLING, offering for SALE,
importing, or otherwise practicing the PATENT RIGHTS outside of the LICENSED FIELD. UNIVERSITY shall be free to grant commercial licenses to the PATENT RIGHTS to third parties in all fields outside the LICENSED FIELD. 

  
 5 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 2.07 Publication. LICENSEE agrees that UNIVERSITY shall have a right to publish any
UNIVERSITY research results or UNIVERSITY technical data related to or arising out of the PATENT RIGHTS in accordance with UNIVERSITY’s general policies and that this AGREEMENT shall not restrict, in any fashion, UNIVERSITY’s right to
publish. 
 Section 2.08 Governmental Rights. LICENSEE understands that the PATENT RIGHTS were developed under a funding agreement with the
Government of the United States of America (“GOVERNMENT”) and that the GOVERNMENT may have certain rights relative thereto. Thus, notwithstanding anything hereunder, any and all licenses and other rights granted hereunder are limited by
and subject to the rights and requirements of the GOVERNMENT which may arise out of its sponsorship of the research which led to the conception or reduction to practice of the PATENT RIGHTS. The GOVERNMENT is entitled, as a right, under the
provisions of 35 U.S.C. §§ 200-212 and applicable regulations of Title 37 of the Code of Federal Regulations: (i) to a nonexclusive, nontransferable, irrevocable,
paid-up license to practice or have practiced for or on the behalf of the GOVERNMENT any of the PATENT RIGHTS throughout the world and (ii) to exercise march in rights on PATENT RIGHTS. This AGREEMENT
shall be exclusive, to the extent allowed in accordance with Public Laws 96-517 and 98-620 in the LICENSED FIELD and is explicitly made subject to the GOVERNMENT’s
rights under such GOVERNMENT funding agreement and any applicable law or regulation. If there is a conflict between the GOVERNMENT funding agreement, applicable law or regulation and this AGREEMENT, the terms of the GOVERNMENT funding agreement,
applicable law or regulation shall prevail. LICENSEE agrees to take any actions necessary to enable UNIVERSITY to satisfy its obligations with the GOVERNMENT relating to the PATENT RIGHTS. LICENSEE agrees, during the period of exclusivity of this
license in the United States, that any LICENSED PRODUCT produced for SALE in the United States will be manufactured substantially in the United States as required by 35 U.S.C. § 204. 

Article III. PAYMENTS 
 Section 3.01
License Payments: In consideration of rights granted by UNIVERSITY to LICENSEE under this AGREEMENT, LICENSEE will pay UNIVERSITY the following: 
  

	 	(a)	 License Execution Payment. LICENSEE shall pay to UNIVERSITY a nonrefundable license execution fee in the
amount of one hundred thousand dollars ($100,000), due and payable within [**] from when this AGREEMENT is fully executed. 

  

	 	(b)	 Annual Maintenance Fee. LICENSEE shall pay to UNIVERSITY an annual license maintenance fee (“ANNUAL
MAINTENANCE FEE”) of [**] dollars ($[**]). This ANNUAL MAINTENANCE FEE shall be due on each anniversary of the EFFECTIVE DATE during the term of this AGREEMENT and shall be fully creditable towards any Minimum Annual Royalty Payment owed as
specified in Section 3.01(d). 

  

	 	(c)	 Running Royalty / Earned Royalty. LICENSEE shall pay UNIVERSITY: 

 

	 	(i)	 A running royalty equal to [**] percent ([**]%) of NET SALES for LICENSED PRODUCTS SOLD by LICENSEE or
SUBLICENSEES in the LICENSED TERRITORY regardless of where LICENSED PRODUCTS are manufactured (hereinafter “SALES ROYALTY”); or, 

  
 6 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(ii)	 A running royalty equal to [**] percent ([**]%) of NET SALES for LICENSED PRODUCTS manufactured, used,
imported, distributed, or otherwise transferred in the LICENSED TERRITORY and SOLD by LICENSEE or SUBLICENSEES outside of the LICENSED TERRITORY (hereinafter “MANUFACTURING ROYALTY”). 

The SALES ROYALTY and the MANUFACTURING ROYALTY are each a “ROYALTY.” 

 

	 	(iii)	 Each ROYALTY accrues when LICENSED PRODUCTS are invoiced or shipped, whichever occurs first.

  

	 	(d)	 Minimum Annual Royalty Payment. LICENSEE shall pay to UNIVERSITY a
non-refundable minimum annual royalty of [**] dollars ($[**]) for each LICENSED PRODUCT in the United States due and payable beginning the end of the calendar year of first commercial SALE for each LICENSED
PRODUCT. Each minimum annual royalty payment is creditable against SALES ROYALTY due UNIVERSITY during the twelve (12) month period following each date the minimum annual royalty becomes due and is subsequently paid. For the avoidance of doubt,
such minimum annual royalty shall be considered a payment in advance of royalties yet to accrue. 

  

	 	(e)	 Milestone Payments. LICENSEE shall pay UNIVERSITY a milestone payment fee in accordance with the
following schedule: 

  

	 	(i)	 Regulatory Milestone Payments to be paid for each LICENSED PRODUCT: 

 

	 	1)	 Upon [**] for each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]). 

 

	 	2)	 Upon [**], with each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]). 

 

	 	3)	 Upon [**] with each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]). 

 

	 	4)	 Upon [**] with each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]). 

 

	 	5)	 Upon [**] of each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]). 

In the event that a milestone is met and a prior milestone has not been met, then, the later and all prior unpaid milestone amounts will be
combined and will be due upon the occurrence of the later milestone. For example, a [**] would result in LICENSEE owing [**] dollars ($[**]) due upon [**]. 

For clarity, for each LICENSED PRODUCT achieving regulatory approval in the US, LICENSEE will owe UNIVERSITY a total amount in Regulatory
Milestone Payments of seven hundred sixty two thousand five hundred dollars ($762,500) for such LICENSED PRODUCT. 

  
 7 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(ii)	 Sales Milestone Payments to be paid for each LICENSED PRODUCT include: 

 

	 	1)	 Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay
[**] dollars ($[**]). 

  

	 	2)	 Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay
[**] dollars ($[**]) 

  

	 	3)	 Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay
[**] dollars ($[**]) 

  

	 	4)	 Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay
[**] dollars ($[**]). 

 By way of example, should LICENSEE develop two LICENSED PRODUCTS (i.e., two different commercial
products), then each of the foregoing milestones shall be payable for each of LICENSED PRODUCTS. Milestone fees are non-refundable. Royalty payments in a given license year shall not be creditable against any
milestone fees. 
 Section 3.02 Sublicense Royalties and Fees 
  

	 	(a)	 Sublicensee Earned Royalty. For the avoidance of doubt, LICENSEE shall pay to UNIVERSITY an amount for
NET SALES made by SUBLICENSEES (including through multiple tiers) equal to what LICENSEE would have been required to pay to UNIVERSITY had LICENSEE made such NET SALES.

 

	 	(b)	 Other Sublicensee Payments. In consideration of rights granted by UNIVERSITY to LICENSEE under this
AGREEMENT, in addition to the SUBLICENSEE earned royalty of Section 3.02(a), LICENSEE further agrees to pay UNIVERSITY an additional royalty on all other non-NET SALES revenue (i.e., not including the
ROYALTIES payable in Section 3.01(c)) or consideration received from any SUBLICENSEE (“SUBLICENSE REVENUE”) as set forth in this Section 3.02(b)(i) except as provided in Section 3.02(b)(ii). Such revenue or other
consideration shall include, but not be limited to all option fees, license issue fees (up-front payments), license maintenance fees, milestones, equity, joint marketing fees, and research and development
funding in excess of LICENSEE’s cost of performing such research and development, and all other royalty payments (other than the earned royalty specified in Section 3.02(a)). Notwithstanding the foregoing, SUBLICENSE REVENUE shall not
include research and development funding and/or patent cost reimbursement provided to LICENSEE by SUBLICENSEE, equity purchases at fair market value, loans by SUBLICENSEE to LICENSEE at fair market rates, and any royalty payments as specified in
Sections 3.01(c) and 3.02(a). 

  

	 	(i)	 The additional royalty on all other revenue or consideration received from any SUBLICENSEE shall be as
applicable to rights sublicensed in OTOFERLIN LICENSED SUBFIELD and [**] LICENSED SUBFIELD: 

  
 8 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	1)	 [**]% if sublicensed [**] 

 

	 	2)	 [**]% if sublicensed [**] but before [**], 

 

	 	3)	 [**]% if sublicensed [**], but before [**] 

 

	 	4)	 [**]% if sublicensed [**], but before [**] 

 

	 	5)	 [**]% if sublicensed [**], but before [**] 

 

	 	6)	 [**]% if sublicensed [**]. 

By way of example, if LICENSEE enters into a sublicense agreement [**] in which a SUBLICENSEE later pays LICENSEE a [**] percent ([**]%)
royalty on NET SALES for LICENSED PRODUCTS SOLD in the LICENSED TERRITORY and a [**] dollar ($[**]) milestone payment based on sales made by SUBLICENSEE, then LICENSEE shall pay UNIVERSITY the [**] percent ([**]%) SALES ROYALTY pursuant to
Section 3.01(c)(i) and Section 3.02(a) and $[**] pursuant to Section 3.02(b)(i)1). 
  

	 	(ii)	 In the event that the PATENT RIGHTS are sublicensed [**]. LICENSEE shall [**] UNIVERSITY. If UNIVERSITY [**],
then the UNIVERSITY and LICENSEE will [**]. The PARTIES will [**]. In no event shall [**] set forth in [**]. 

  

	 	(c)	 Royalty Stacking. If, in order to make, use, import or SELL LICENSED PRODUCTS under the PATENT RIGHTS,
it becomes necessary for LICENSEE to obtain a royalty-bearing license to other patent(s) owned or controlled by a third party (“THIRD PARTY PATENTS”) to avoid infringement of the THIRD PARTY PATENTS because they dominate the PATENT RIGHTS
to the extent that the LICENSED PRODUCTS could not be made, used, or sold without infringing the THIRD PARTY PATENTS, then the SALES ROYALTY in Section 3.01(c)(i) shall be adjusted by an amount equal to [**] percent ([**]%) of the royalty rate
paid to the THIRD PARTY, provided that in no event shall the royalties otherwise due UNIVERSITY be less than [**] percent ([**]%) of the royalties that would be payable to UNIVERSITY absent the effects of this section. Thus, for clarity, the SALES
ROYALTY in Section 3.01(c)(i) shall never be reduced below [**] percent ([**]%). Furthermore, the MANUFACTURING ROYALTY in Section 3.01(c)(ii) is not subject to adjustments and shall never be reduced below [**] percent ([**]%).

 Section 3.03 How Payments are Made. All payments to UNIVERSITY pursuant to this AGREEMENT shall be paid in U.S. dollars.
Conversion of foreign currency to U. S. dollars shall be made at the conversion rate existing in the United States (as reported in the in the Wall Street Journal) on the last working day of each ROYALTY PERIOD. Such payments shall be without
deduction of exchange, collection or other charges. Such payments shall be made payable to The Curators of the University of Missouri and shall be mailed to the Office of Intellectual Property Administration, 475 McReynolds Hall, Columbia, MO 65211.

 Section 3.04 Payment Deadlines. Unless stipulated otherwise, all payments due UNIVERSITY hereunder shall be made within [**] after the end of
each ROYALTY PERIOD. Late payments shall be subject to an interest charge of [**] percent ([**]%) per month, compounded monthly. LICENSEE shall also be responsible for payment of all bank transfer charges. 

  
 9 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 3.05 No Taxes. Taxes and/or other governmental charges or fees shall not be levied on
the payments made to UNIVERSITY under this Article III and shall not be deducted from any payments due UNIVERSITY under this Article III. LICENSEE shall be responsible for any and all taxes, fees, levies, duties, or other charges imposed by the
government of any country on such payments. 
 Section 3.06 Default Payment. In the event of LICENSEE’s failure to pay any amount owing to
UNIVERSITY under the terms of this AGREEMENT, and if it becomes necessary for UNIVERSITY to engage outside legal counsel to collect such payment, and if UNIVERSITY is successful in collecting such payment wherein success is defined as either
(1) LICENSEE voluntarily paying as part of a settlement or (2) a court finding that LICENSEE needed to pay, LICENSEE shall pay all expenses, costs and attorneys’ fees incurred by UNIVERSITY in connection therewith. Further, in the
event that UNIVERSITY brings a lawsuit against a SUBLICENSEE for failure to pay any royalties or other payments due, and if UNIVERSITY is successful in collecting such payment wherein success is defined as either (1) SUBLICENSEE voluntarily
paying as part of a settlement or (2) a court finding that SUBLICENSEE needed to pay, LICENSEE shall pay all expenses, costs and attorneys’ fees incurred by UNIVERSITY in connection therewith. LICENSEE shall use commercially reasonable
efforts to enforce any SUBLICENSEE obligation or payment if the breach of that obligation or payment would be a breach of this AGREEMENT if made by LICENSEE. To the extent that LICENSEE may as to UNIVERSITY cure such breach by its own performance,
e.g., by making any payments due to UNIVERSITY regardless of SUBLICENSEE’s failure to pay LICENSEE, then LICENSEE shall do so at its own risk and expense. 

Section 3.07 Challenge to Patent Rights. During the term as set forth in Section 10.01, in the event that LICENSEE or one or more of its
SUBLICENSEES directly or indirectly: (a) issues a press release, public announcement, news release alleging invalidity or unenforceability of any claim within the PATENT RIGHTS; or (b) asserts a claim or counterclaim in the courts or
before the applicable governmental agency (e.g., the United States Patent Trial and Appeal Board) seeking to attack, invalidate or render unenforceable any claim within the PATENT RIGHTS; or (c) assists a third party with either or both
(a) or (b) (each of (a), (b), or (c) being a “CHALLENGE EVENT”), then LICENSEE or its SUBLICENSEE as applicable shall provide at least [**] written notice to UNIVERSITY prior to initiating such a CHALLENGE EVENT, along with a
copy of any prior art which forms the basis for the CHALLENGE EVENT and a claim-by-claim detailed analysis of patent invalidity and/or unenforceability. Upon the
occurrence of a CHALLENGE EVENT, UNIVERSITY, shall have the right, but not the obligation, to terminate this AGREEMENT with respect to such LICENSEE and/or SUBLICENSEE by providing written notice of the same. In the event that UNIVERSITY elects not
to terminate this AGREEMENT, then all payments due under Article III by LICENSEE or SUBLICENSEE(s) as applicable shall [**]. Moreover, should the outcome of any such action or proceeding be unsuccessful, then LICENSEE and/or SUBLICENSEE challenging
such claim shall pay (1) [**] all payments after the pendency of the aforementioned action and (2) UNIVERSITY’s costs, expenses, and reasonable attorneys’ fees incurred in such action. An action or proceeding shall be deemed
“unsuccessful” for purposes of this Section 3.07 if: (i) the proceeding or lawsuit is terminated for any reason prior to a settlement or judgment from which no appeal can be or is taken; (ii) one or more of the claims within
the PATENT RIGHTS challenged by said lawsuit remain valid and enforceable after any such settlement or judgment is in effect; or (iii) if LICENSEE would still require a license to any of the PATENT RIGHTS to SELL any of its products after any
such settlement or judgment is in effect. Any such judicial challenge by LICENSEE or a SUBLICENSEE shall be brought in the courts of Missouri, and LICENSEE and its SUBLICENSEE agree not to challenge personal jurisdiction in that forum. LICENSEE or
such SUBLICENSEE shall not be relieved from any payments that accrue before any decision invalidating a claim within the PATENT RIGHTS or a claim not involved in such decision. LICENSEE or such SUBLICENSEE shall have no right to recoup any such
payments paid before or during the period of challenge. 

  
 10 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Article IV. REPORTING 

Section 4.01 Commercialization Plan. Prior to signing this AGREEMENT, LICENSEE has provided to UNIVERSITY a written plan (hereinafter
“COMMERCIALIZATION PLAN”) for the LICENSED PRODUCT within the respective LICENSED FIELD and within the LICENSED TERRITORY to be introduced by LICENSEE into commercial use. The COMMERCIALIZATION PLAN shall include, without limitation:
(a) planned research and development activities and (b) milestones and evidence of sufficient financial resources to successfully implement the COMMERCIALIZATION PLAN and ensure that LICENSED PRODUCT will be kept reasonably available to
the public. Such COMMERCIALIZATION PLAN is incorporated as Appendix B. 
 Section 4.02 First Sale. LICENSEE shall report to UNIVERSITY the date
of first SALE of LICENSED PRODUCTS in LICENSED TERRITORY within [**] of occurrence. An exemplary report format is set forth as Appendix C. 

Section 4.03 Reporting. Within [**] after each ROYALTY PERIOD following the first SALE of LICENSED PRODUCT, whether SOLD by LICENSEE or its
SUBLICENSEE, if any exists, LICENSEE must deliver to UNIVERSITY a true and accurate written report, even if no payments are due UNIVERSITY, giving the particulars of the business conducted by LICENSEE and its SUBLICENSEE(s) during the ROYALTY PERIOD
as are pertinent to calculating payments hereunder. This report will include at least: 
  

	 	(a)	 the quantities of LICENSED PRODUCT produced or manufactured; 

 

	 	(b)	 the total NET SALES, including any deductions applicable as provided in Section 1.06;

  

	 	(c)	 the exchange rate used; 

 

	 	(d)	 the offsets of minimum annual royalties or other offsets allowed under this AGREEMENT; 

 

	 	(e)	 the method used to calculate the royalties thereon; 

 

	 	(f)	 the total SALES ROYALTY computed and due UNIVERSITY; 

  
 11 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(g)	 the royalties due UNIVERSITY on additional payments from SUBLICENSEE(s) under Section 3.02; and

  

	 	(h)	 the names and addresses of all SUBLICENSEES of LICENSEE. 

If no payment is due, LICENSEE shall so report to UNIVERSITY. An exemplary report format is set forth in Appendix D. This report shall identify the issued
patents and/or patent applications under the PATENT RIGHTS that cover the particular LICENSED PRODUCT being reported. LICENSEE shall direct its authorized representative to certify that reports required hereunder are correct to the best of
LICENSEE’s knowledge and information. Failure to provide reports as required under this Article shall be a material breach of this AGREEMENT. 

LICENSEE shall provide sufficient data for UNIVERSITY to verify the royalty calculations and any reasonable additional information UNIVERSITY requires to
determine LICENSEE’s satisfaction of the reporting requirements hereunder or to clarify the information contained in reports provided by LICENSEE. LICENSEE shall provide such additional information to UNIVERSITY within [**] of receiving a
request from UNIVERSITY. Simultaneously with the delivery of each report, LICENSEE must pay to UNIVERSITY the amount, if any, due for the period of each report. 

Section 4.04 Annual Commercialization Report. On or before each anniversary of the EFFECTIVE DATE, irrespective of having a first SALE or offer
for SALE, LICENSEE must deliver to UNIVERSITY a written annual report as to LICENSEE’s (and any SUBLICENSEE’s) efforts and accomplishments during the preceding year in diligently commercializing LICENSED PRODUCT in the LICENSED FIELD,
including, 
  

	 	(a)	 Material research and development progress, 

 

	 	(b)	 regulatory filings and approvals, 

 

	 	(c)	 manufacturing, 

  

	 	(d)	 sublicensing activities, 

 

	 	(e)	 marketing and sales, 

 

	 	(f)	 total capital raised (not necessarily related to LICENSED PRODUCT), 

 

	 	(g)	 LICENSEE’s (and, if applicable, SUBLICENSEE’s) commercialization plans for the upcoming year.

 LICENSEE shall also promptly provide any reasonable additional information UNIVERSITY requested to evaluate LICENSEE’S performance
under this AGREEMENT. An exemplary report format is set forth in Appendix E. 

  
 12 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 4.05 Records. LICENSEE shall keep full, true and accurate books of account containing
all particulars that may be necessary for the purpose of showing the amounts payable to UNIVERSITY. The books of account shall be kept at LICENSEE’s principal place of business or the principal place of business of the appropriate division of
LICENSEE to which this AGREEMENT relates. The books, ledgers, records, and the supporting data shall be open at all reasonable times for [**] following the end of the calendar year to which they pertain, for the inspection by UNIVERSITY or its
representatives for the purpose of verifying LICENSEE’s royalty statements or compliance in other respects with this AGREEMENT. If the amounts due to UNIVERSITY are determined to have been underpaid, LICENSEE will pay the amount of such
underpayment and interest on the amount of such underpayment with interest accumulating at the rate as set forth in Section 3.04 accruing from the date such payment was originally due to UNIVERSITY. Should such inspection lead to the discovery
of (a) a greater than [**] percent ([**]%) discrepancy or (b) [**] dollars ($[**]) or more, whichever would be greater, in reporting to UNIVERSITY’s detriment, LICENSEE agrees to pay the full cost of such inspection and audit. 

Article V. DUE DILIGENCE 

Section 5.01 LICENSEE shall use reasonable commercial efforts to effect introduction of the LICENSED PRODUCT into the commercial market as soon as
practicable, consistent with sound and reasonable business practices and judgment; thereafter, until the expiration or termination of this AGREEMENT, LICENSEE shall keep LICENSED PRODUCT reasonably available to the public. 

Section 5.02 UNIVERSITY shall have the right, at UNIVERSITY’s sole discretion, to either terminate or render this license nonexclusive in an
individual LICENSED FIELD and/or individual country or countries within the LICENSED TERRITORY if LICENSEE or its SUBLICENSEE (if applicable): 
  

	 	(a)	 In the OTOFERLIN LICENSED SUBFIELD: 

 

	 	(i)	 Has not [**] for a LICENSED PRODUCT targeting the otoferlin gene by [**]. 

 

	 	(ii)	 Has not [**] for a LICENSED PRODUCT targeting the otoferlin gene [**] by [**]. 

 

	 	(iii)	 Has not [**] for a LICENSED PRODUCT [**] targeting the otoferlin gene by [**]. 

 

	 	(iv)	 Has not [**] for a LICENSED PRODUCT [**] targeting the otoferlin gene by [**]. 

 

	 	(b)	 In the [**] LICENSED SUBFIELD: 

 

	 	(i)	 Has not [**] of the [**] gene [**] by [**]. 

 

	 	(ii)	 Has not [**] for a LICENSED PRODUCT targeting the [**] gene by [**]. 

 

	 	(iii)	 Has not [**] for a LICENSED PRODUCT targeting the [**] gene [**] by [**]. 

 

	 	(iv)	 Has not [**] for a LICENSED PRODUCT [**] targeting the [**] gene by [**]. 

 

	 	(v)	 Has not [**] for a LICENSED PRODUCT [**] targeting the [**] gene by [**]. 

 

	 	(c)	 Achieved [**] for any LICENSED PRODUCT [**] within [**]. 

  
 13 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Article VI. INDEMNITY, INSURANCE, WARRANTIES, DAMAGES 

Section 6.01 Indemnity. LICENSEE shall, and will require SUBLICENSEES to, at all times during the term of this AGREEMENT and thereafter,
indemnify, defend and hold UNIVERSITY, its current or former Curators, employees, agents, and affiliates, harmless from any claim, proceeding, suit, demand, expense, loss, penalty, judgment, or liability of any kind whatsoever, including costs,
expenses and reasonable attorneys’ fees, resulting from, related to, arising out of, or in connection with (a) the design, development, production, manufacture, shipping, use, performance, importation, SALE, advertisement, labeling,
promotion, or patent marking of the LICENSED PRODUCT by LICENSEE or its SUBLICENSEES, or end users, including but not limited to (i) any infringement or misappropriation of a patent, copyright, trade secret or other intellectual property or
proprietary right of any third party or (ii) any product liability claims, such as those involving the death of or injury to any person or persons or damage to property; or (b) any breach of any obligation, covenant, representation, or
warranty by LICENSEE or its SUBLICENSEES hereunder; or (c) the production, use or SALE of any product, process or service identified, characterized or otherwise developed with the aid of the PATENT RIGHTS by LICENSEE or its SUBLICENSEES; or
(d) any violation of applicable law by LICENSEE, or its SUBLICENSEES; or (e) the exercise of LICENSEE’s rights under this AGREEMENT. If any such claims or causes of action are made, UNIVERSITY shall be defended by counsel selected by
LICENSEE, subject to UNIVERSITY’s approval, which shall not be unreasonably withheld. UNIVERSITY reserves the right to be represented by its own counsel at its own expense. 

Section 6.02 Insurance. At such time as any LICENSED PRODUCT is being commercially SOLD (other than for the purpose of obtaining regulatory
approvals) by LICENSEE, a SUBLICENSEE, or a subsidiary or agent of LICENSEE, LICENSEE shall at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $[**] per occurrence and naming
UNIVERSITY, its Curators, employees, agents, and affiliates, as additional insureds. Such commercial general liability insurance shall provide (a) product liability coverage and (b) contractual liability coverage for LICENSEE’s
indemnification under this AGREEMENT unless the UNIVERSITY Risk and Insurance Management expressly waives such requirement in writing. Such insurance will be considered primary as to any other valid and collectible insurance, but only as to acts of
the named insured. Any carrier providing coverage shall have a minimum “Best” rating of “A-XIII”. The minimum amounts of insurance coverage required shall not be construed to create a limit
of LICENSEE’s liability with respect to its indemnification under this AGREEMENT. 
 LICENSEE shall maintain such commercial general liability
insurance beyond the expiration or termination of this AGREEMENT during (i) the period that any product, process, or service, relating to, or developed pursuant to this AGREEMENT is being commercially SOLD by LICENSEE or its SUBLICENSEE and
(ii) a reasonable period after the period referred to in (i) above which in no event shall be less than [**]. 

  
 14 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 LICENSEE shall provide Workers’ Compensation in accordance with applicable state statutes or provide
evidence of monopolistic state coverage. LICENSEE shall also purchase Employers Liability insurance with the following limits: $[**] each accident, disease each employee and disease policy limit 

LICENSEE shall provide UNIVERSITY with written evidence of the insurance requirements of this Section 6.02 within [**] after such insurance becomes
necessary pursuant to this AGREEMENT. LICENSEE shall provide UNIVERSITY with written notice at least [**] prior to the cancellation, non-renewal or material change in such insurance; if LICENSEE does not
obtain replacement insurance providing comparable coverage within such [**] period, UNIVERSITY shall have the right to terminate this AGREEMENT effective at the end of such [**] period without notice or any additional waiting periods. It is agreed
that the insurance required is required in the public interest and UNIVERSITY does not assume any liability for acts of LICENSEE, their officers, agents, and employees or of a SUBLICENSEE, their officers, agents, and employees, in connection with
the granting of this AGREEMENT. 
 If LICENSEE elects to self-insure all or part of the limits described above, such self-insurance program must be
acceptable to UNIVERSITY’s Risk and Insurance Management department. 
 Section 6.03 Disclaimer of Warranties. THE PATENT RIGHTS ARE
DELIVERED “AS IS” IN EVERY RESPECT. UNIVERSITY, ITS CURRENT OR FORMER CURATORS, EMPLOYEES, AGENTS, AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF COMMERCIAL UTILITY, MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS,
WHETHER ISSUED OR PENDING, OR THAT THE MANUFACTURE, USE, IMPORTATION OR SALE OF THE LICENSED PRODUCT OR THAT THE PRACTICE OF THE PATENT RIGHTS WILL NOT INFRINGE OR MISAPPROPRIATE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF ANY THIRD
PARTY.  
 Section 6.04 Damages Exclusion / Limitation of Remedies. IN NO EVENT SHALL UNIVERSITY, ITS CURRENT OR FORMER CURATORS,
EMPLOYEE, AGENTS, AND AFFILIATES BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES OF ANY KIND, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT OR IN TORT, INCLUDING NEGLIGENCE OR OTHERWISE, AND INCLUDING
ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, ATTORNEYS’ AND EXPERTS’ FEES, REGARDLESS OF WHETHER UNIVERSITY MAY BE ADVISED, MAY HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY.  

Section 6.05 For the avoidance of doubt, nothing in this AGREEMENT shall be construed as: 

 

	 	(a)	 a warranty or representation by UNIVERSITY as to the validity or scope of any PATENT RIGHTS;

  

	 	(b)	 a warranty or representation by UNIVERSITY that anything made, used, imported, SOLD or otherwise disposed of
pursuant to any license granted under this AGREEMENT is or will be free from infringement of intellectual property rights of third parties; 

  
 15 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(c)	 an obligation by UNIVERSITY to bring or prosecute actions or suits against third parties for patent
infringement; 

  

	 	(d)	 an obligation to furnish any know-how not provided in the PATENT
RIGHTS; or 

  

	 	(e)	 conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other
than PATENT RIGHTS, regardless of whether such patents are dominant or subordinate to the PATENT RIGHTS. 

 Section 6.06
Sublicenses. LICENSEE shall require in any sublicense in which LICENSEE grants to a third party the right to make, have made, use, import, offer to SELL or SELL any LICENSED PRODUCT, provisions that provide UNIVERSITY, its Curators,
employees, agents, and affiliates, comparable protections as those provided UNIVERSITY in this Article VI. LICENSEE shall not, and shall require that its SUBLICENSEES do not, make any statements, representations or warranties whatsoever to any
person or entity, or accept any liabilities or responsibilities whatsoever from any person or entity that are inconsistent with any disclaimer of warranties or damages exclusion / limitation of remedies included in this Article VI. 

Article VII. DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE 

Section 7.01 Ownership and Control of Patents. UNIVERSITY shall have full, complete and sole ownership of any pending applications
and issued patents included in PATENT RIGHTS. UNIVERSITY shall be responsible for the preparation, filing, prosecution and maintenance of the patent applications and issued patents included in the PATENT RIGHTS. UNIVERSITY, either directly or
through its attorneys at UNIVERSITY’s option, shall first consult with LICENSEE or its attorneys as to the preparation, filing, prosecution, and maintenance of such patent applications and issued patents and shall furnish to LICENSEE or its
attorneys copies of significant documents it receives relevant to any such preparation, filing, prosecution or maintenance. LICENSEE shall cooperate with UNIVERSITY in such preparation, filing, prosecution, and maintenance. LICENSEE agrees to hold
such information confidential and to use the information provided by UNIVERSITY only for the purpose of advancing the PATENT RIGHTS and shall return all such information to UNIVERSITY upon termination of LICENSEE’s rights in any particular
patent application or issued patent under Section 7.05 or upon termination or expiration of this AGREEMENT. 
 Section 7.02 Common Legal
Interest.  
  

	 	(a)	 Existence of a Common Legal Interest. UNIVERSITY and LICENSEE confirm that they have had and continue to
have a common legal interest in preparation, filing, prosecution and maintenance of the patent applications and issued patents included in the PATENT RIGHTS, and including any infringement/validity litigation arising therefrom (the “COMMON
INTEREST”). 

  
 16 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(b)	 Common Interest Information. UNIVERSITY and LICENSEE agree that “COMMON INTEREST INFORMATION”
shall mean any and all information shared between UNIVERSITY and LICENSEE, or their counsel, to advance their common interest and/or relating in any way to the COMMON INTEREST, including, but not limited to, information exchanged through oral,
written, electronic or other means, documents, prior art, factual material, mental impressions, strategies, legal theories and analysis, memoranda, expert analysis and opinions, interviews and interview reports, witness statements and other
information, analysis and conclusions belonging to either or both PARTIES and communications between the PARTIES and their counsel. 

  

	 	(c)	 Application of Privilege. UNIVERSITY and LICENSEE intend this Section 7.02 shall enable them, to
the fullest extent permitted by law, to share COMMON INTEREST INFORMATION while preserving their common interest privilege, joint defense privilege, attorney-client privilege, litigation privilege, attorney work product protection or any other
related or applicable privilege or protection, or other exemptions from disclosure that might attach thereto. 

  

	 	(d)	 Use, Confidentiality and Marking.  

 

	 	(i)	 Each PARTY agrees that the COMMON INTEREST INFORMATION it receives from the other PARTY or developed jointly
shall be only used for the purpose of the COMMON INTEREST. 

  

	 	(ii)	 At all times, any COMMON INTEREST INFORMATION disclosed by UNIVERSITY and LICENSEE or any of their counsel
shall be maintained in confidence by the other PARTY and their counsel unless and until permission is given in writing by the disclosing PARTY or except as provided in Section 7.02(e). 

 

	 	(iii)	 UNIVERSITY and LICENSEE may in their discretion label as “COMMON INTEREST INFORMATION” materials
exchanged pursuant to this AGREEMENT. However, failure to so mark or label any material shall neither exclude that material from the scope of COMMON INTEREST INFORMATION nor constitute a waiver of any privilege or a waiver of any right or obligation
created by this AGREEMENT. 

  

	 	(e)	 Third Party Requests. If any third party requests or demands any COMMON INTEREST INFORMATION from
LICENSEE, LICENSEE will immediately notify the UNIVERSITY. All necessary steps will be taken by the LICENSEE to whom the request is made to permit the assertion of all applicable rights, privileges, doctrines and rules of protection with regard to
the COMMON INTEREST INFORMATION. Without limiting the foregoing, upon receipt by a LICENSEE of a summons, subpoena, or open records request requesting access to, or production of COMMON INTEREST MATERIALS provided by UNIVERSITY, LICENSEE shall
immediately: (i) notify the UNIVERSITY and provide not less than [**] notice before production; (ii) take all necessary steps to defend against and resist the request; and (iii) cooperate with UNIVERSITY in defending against and
resisting this request. LICENSEE agrees to inform the person or entity seeking the COMMON INTEREST INFORMATION that such materials are privileged and may not be disclosed unless so ordered by the court. LICENSEE shall not be deemed to be in breach
of this AGREEMENT if that LICENSEE communicates information because compelled to do so by law or a court of competent jurisdiction. 

  
 17 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(f)	 Effect of Termination or Expiration on Common Interest Information. Upon termination or expiration of
this AGREEMENT, any COMMON INTEREST INFORMATION made available by either UNIVERSITY or LICENSEE prior to such termination or expiration shall continue to be governed by the terms of this AGREEMENT. Further, the PARTY shall return or destroy all
COMMON INTEREST INFORMATION received from the other PARTY in its possession that is fixed in a tangible form of expression to the other PARTY within [**] of any request from the other PARTY. 

 

	 	(g)	 Disqualification. This Section 7.02 is not intended nor shall it be deemed to affect the
independent and separate representation of a PARTY by its counsel. Further, this AGREEMENT shall not affect the ethical, fiduciary, or other obligations inherent in those attorney-client relationship other than to extend the cloak of confidentiality
and privilege to the COMMON INTEREST INFORMATION. Neither the existence of this AGREEMENT nor the exchange of COMMON INTEREST INFORMATION pursuant to it, or any claim which may arise between the PARTIES in connection with the PATENT RIGHTS shall be
used as a basis for a claim that any counsel to either UNIVERSITY or LICENSEE is disqualified from representing such PARTY. 

  

	 	(h)	 Memorialization. Prior to execution of this AGREEMENT, the PARTIES may have shared information or
materials with one another that would be considered COMMON INTEREST INFORMATION. The PARTIES hereby state their intention and belief, and they hereby agree that such information is subject to the same legal privileges and protections as though it
had been shared after the execution of this AGREEMENT. Without limiting the foregoing, this AGREEMENT memorializes an understanding between the PARTIES that has existed since before the PARTIES shared any COMMON INTEREST INFORMATION in connection
with the PATENT RIGHTS and the terms of this AGREEMENT apply to any COMMON INTEREST INFORMATION that was shared between the PARTIES and/or their counsel before the EFFECTIVE DATE. 

Section 7.03 Patent Expenses. LICENSEE shall reimburse UNIVERSITY for [**] PATENT EXPENSES as a separate payment apart from any royalties or other
revenues owed UNIVERSITY as described herein. For PATENT EXPENSES incurred prior to the EFFECTIVE DATE, LICENSEE shall pay [**] dollars ($[**]); such reimbursement by LICENSEE shall be due and payable within [**] of execution of this AGREEMENT. For
all future PATENT EXPENSES incurred after the EFFECTIVE DATE, reimbursements by LICENSEE shall be [**]. Reimbursement of future PATENT EXPENSES incurred after the EFFECTIVE DATE shall be due within [**] of receipt of UNIVERSITY’s invoice by
LICENSEE, and shall be non-refundable and non-creditable. Late payment of invoices of PATENT EXPENSES received by LICENSEE from UNIVERSITY shall be subject to interest
charges of [**] percent ([**]%) per month. 

  
 18 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 7.04 Entity Status. LICENSEE shall have a continuing obligation to keep UNIVERSITY and
its patent counsel responsible for the PATENT RIGHTS informed of the entity status (large entity, small entity, and micro entity) of LICENSEE and all its SUBLICENSEES. LICENSEE agrees to give UNIVERSITY prompt notice of a change in any entity status
of it or any SUBLICENSEE. A statement or future statement by LICENSEE and/or its SUBLICENSEE as to its entity status constitutes a representation that is subject to indemnity under Section 6.01. 

Section 7.05 Termination of Patent Rights. By written notification to UNIVERSITY at least [**] in advance of any filing or response deadline or
fee due date (i.e., a date by which an action must be taken to avoid payment of a late fee), LICENSEE may elect not to have a particular patent application filed in a particular country or not to pay expenses associated with prosecuting or
maintaining any particular patent application or issued patent, provided that LICENSEE pays for all PATENT EXPENSES associated with the particular patent application or issued patent incurred up to UNIVERSITY’s receipt of such notification.
LICENSEE’s failure to provide a timely notification shall be considered by UNIVERSITY to be LICENSEE’s consent that it expressly wishes to support any particular issued patent(s) or patent application(s). Upon notice that LICENSEE elects
not to have a particular patent application filed or prosecuted or issued patent maintained in any particular country, or not to reimburse UNIVERSITY for all PATENT EXPENSES associated with prosecuting or maintaining any patent application or
patent, UNIVERSITY may at its sole discretion elect to file, prosecute, and/or maintain such particular patent applications or issued patents at its own expense and for its own benefit, and any rights or license granted under this AGREEMENT held by
LICENSEE or SUBLICENSEE(s) with respect to such patent application(s) or issued patent(s) shall be irrevocably terminated, forfeited, and relinquished. For the avoidance of doubt, LICENSEE and each SUBLICENSEE shall have no right to share in any
revenue derived from such particular patent application or issued patents. 
 Article VIII. INFRINGEMENT OF PATENT RIGHTS 

Section 8.01 Notifications. LICENSEE shall promptly inform UNIVERSITY in writing of any alleged infringement of the PATENT RIGHTS by a third party
and shall provide UNIVERSITY with any available evidence thereof. LICENSEE shall not notify a third party of such infringement of PATENT RIGHTS without first consulting with UNIVERSITY. 

Section 8.02 Enforcement. For so long as the license granted herein is exclusive, LICENSEE, at its expense, shall have the right to enforce PATENT
RIGHTS against infringement by third parties solely in the LICENSED FIELD. All recovery from any enforcement of the PATENT RIGHTS in the LICENSED FIELD, including any cash or other consideration received by way of judgment, settlement or compromise
(hereinafter “RECOVERY”) shall be allocated in the following order: (a) to LICENSEE and UNIVERSITY for reimbursement in pro rata proportions of their costs, fees, and other related expenses to the extent that each PARTY paid for such
costs, fees and expenses; and (b) any remaining amount shall be allocated to LICENSEE and UNIVERSITY either (i) in pro rata proportion to their costs, fees, and other related expenses with respect to such enforcement to the extent that
each PARTY paid for such costs, fees and expenses, provided or (ii) in proportion to the percentages specified by the royalty sublicensing provisions as specified in Section 3.02(b)(i) at the time of the infringement commences, whichever
results in a larger payment to UNIVERSITY. Before LICENSEE commences a formal legal proceeding with respect to any infringement of PATENT RIGHTS, LICENSEE shall first consult with UNIVERSITY regarding the potential effects such legal proceeding may
have on the public interest. LICENSEE shall not enforce the PATENT RIGHTS against any UNIVERSITY licensees of the PATENT RIGHTS without the prior written consent of UNIVERSITY. UNIVERSITY shall have the right, in its sole discretion, to join such
proceeding at its own expense. In the event that UNIVERSITY is involuntarily joined as a party to an infringement action brought by LICENSEE (including any counterclaim), then LICENSEE shall pay any costs, expenses, and attorneys’ fees incurred
by UNIVERSITY arising out of, relating to, or in connection therewith. In addition, LICENSEE agrees to consult with UNIVERSITY on any significant matters related to the litigation. LICENSEE shall be free to enter into a settlement, consent judgment,
or other voluntary disposition with respect to any such action, provided that any settlement, consent judgment or other voluntary disposition thereof which (i) materially limits the scope, validity, or enforceability of patents included in the
PATENT RIGHTS, (ii) admits fault or wrongdoing on the part of UNIVERSITY or (iii) imposes a financial or other obligation upon the UNIVERSITY, must in the case of (i), (ii), or (iii) be
pre-approved in writing by UNIVERSITY. LICENSEE shall keep UNIVERSITY informed on all actions taken by LICENSEE in its enforcement against an infringer and shall furnish to UNIVERSITY copies of all documents
related thereto. LICENSEE shall indemnify, defend, and hold harmless UNIVERSITY against any order for costs or fees that may be made against UNIVERSITY in such proceeding arising from, related to, or in connection with an act or omission made by
LICENSEE. 

  
 19 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 8.03 Rights of University. In the event that LICENSEE elects not to exercise its right
to bring an infringement action with respect to PATENT RIGHTS pursuant to the above paragraphs, then LICENSEE shall notify UNIVERSITY in writing within [**] of receiving notice that an infringement exists. UNIVERSITY may, at its own expense and
control, following the earlier of (i) such notice from LICENSEE or (ii) the expiration of such [**] period without LICENSEE electing to take any action with respect to such alleged or actual infringement, take steps to defend or enforce
any patent within the PATENT RIGHTS and retain all RECOVERY therefrom without a duty to account to LICENSEE. LICENSEE agrees to cooperate reasonably with UNIVERSITY in any validity or infringement suit or dispute involving the PATENT RIGHTS. 

Article IX. CONFIDENTIALITY 

Section 9.01 Confidential Information Defined. “CONFIDENTIAL INFORMATION” means any and all information not generally known to the
public, whether or not patentable or susceptible to any other form of legal protection, that is identified or designated by UNIVERSITY as being confidential or which, in light of the circumstances under which it was disclosed, whether oral or
written, is reasonably apparent to LICENSEE to be considered confidential or proprietary by UNIVERSITY, including but not limited to information, concepts, designs, processes, specifications, schematics, equipment, processing techniques, technical
information, drawings, diagrams, software (including source code), hardware, control systems, research, test results, manuals, trade secrets, commercialization studies, market studies, and business plans received by LICENSEE from UNIVERSITY except
to the extent LICENSEE can prove by written documentation that such information: 
  

	 	(a)	 was in the public domain at the time of disclosure; 

  
 20 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(b)	 later became part of the public domain through no act or omission or breach of this AGREEMENT by LICENSEE, its
employees, agents, successors or assigns; 

  

	 	(c)	 was lawfully disclosed to LICENSEE by a third party having the right to make such disclosure; or

  

	 	(d)	 was already known by LICENSEE at the time of disclosure; or 

 

	 	(e)	 was independently developed by LICENSEE without the aid, use or application of CONFIDENTIAL INFORMATION
received from UNIVERSITY and such independent development can be properly demonstrated by LICENSEE; or 

  

	 	(f)	 is otherwise required by law or regulation to be disclosed. 

Specific information shall not be deemed to be within the foregoing exceptions merely because it is embraced by more general information within the
exceptions. In addition, any combination of the features shall not be deemed to be within the foregoing exception merely because individual features may be within the exceptions. 

Section 9.02 Restrictions on Disclosure and Use. LICENSEE agrees that (a) all CONFIDENTIAL INFORMATION shall remain the exclusive property of
UNIVERSITY, (b) LICENSEE shall receive and hold the CONFIDENTIAL INFORMATION in strict confidence, (c) LICENSEE shall use the CONFIDENTIAL INFORMATION only for the purposes of this AGREEMENT, and (d) LICENSEE shall not disclose the
CONFIDENTIAL INFORMATION to third parties without the prior written consent of UNIVERSITY, and (e) LICENSEE shall protect the CONFIDENTIAL INFORMATION to the same extent that it protects its own trade secrets and confidential information, but
in no less than commercially reasonable care. 
 Section 9.03 Legally required Disclosures. In the event that LICENSEE receives a request or is
required by deposition, interrogatory, request for documents, subpoena, civil investigative demand, or similar process to disclose any or part or the CONFIDENTIAL INFORMATION, LICENSEE agrees to (a) immediately notify UNIVERSITY in writing of
the existence, terms, and circumstances surrounding such a request or requirement and (b) assist UNIVERSITY in seeking a protective order or other appropriate remedy satisfactory to UNIVERSITY. In the event that such a protective order or other
remedy is not obtained, (a) LICENSEE may disclose that portion of the CONFIDENTIAL INFORMATION which it is legally required to disclose, (b) LICENSEE shall exercise reasonable efforts to obtain assurance that confidential treatment will be
accorded the CONFIDENTIAL INFORMATION to be disclosed and (c) LICENSEE shall give written notice to UNIVERSITY of the information to be disclosed as far in advance of its disclosure as practical. LICENSEE may also disclose CONFIDENTIAL
INFORMATION to governmental or other regulatory agencies in order to obtain approvals to market any LICENSED PRODUCT, but such disclosure may only be to the extent reasonable necessary to obtain approvals. 

Section 9.04 Disclosure to Potential Sublicensee or Assignee. Upon receiving written approval from UNIVERSITY, LICENSEE may disclose the
CONFIDENTIAL INFORMATION to a potential SUBLICENSEE or assignee of LICENSEE in each case on the condition that such potential SUBLICENSEE or assignee agrees to be bound by the confidentiality obligations contained in this AGREEMENT. 

  
 21 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 9.05 Sunshine Law. LICENSEE acknowledges that UNIVERSITY is subject to the Missouri
Sunshine Act, 610 RSMo, and that all agreements, plans, reports, and other information marked “Confidential” shall be treated by UNIVERSITY as confidential only to the extent permitted by law. 

Section 9.06 Survival. LICENSEE’s obligations of confidentiality and non-use shall exist during the
term of this AGREEMENT and for so long as such CONFIDENTIAL INFORMATION remains confidential in accordance with Section 9.01. 

Article X. TERM AND TERMINATION 

Section 10.01 Term. This AGREEMENT shall become effective upon the EFFECTIVE DATE and, unless sooner terminated in accordance with any of the
provisions herein, shall remain in full force in the LICENSED TERRITORY until the expiration of the last to expire patent or last to be abandoned patent application included in the PATENT RIGHTS. 

Section 10.02 Right to Terminate by Licensee. LICENSEE shall have the right to terminate this AGREEMENT at any time on six (6) months notice
to UNIVERSITY. 
 Section 10.03 Breach. In the event that either PARTY defaults or breaches any of the provisions of this AGREEMENT, the other
PARTY shall have the right to terminate this AGREEMENT by giving written notice to the defaulting PARTY; provided, however, that if the defaulting PARTY cures the default within [**] after the notice shall have been given, this AGREEMENT shall
continue in full force and effect. The failure on the part of either of the PARTIES hereto to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right nor operate to bar the exercise or
enforcement thereof at any time or times thereafter. In relation to Article III (payments) and Section 7.03 (patent expenses), LICENSEE’s opportunity to cure a breach shall apply only to LICENSEE’s first two notices of a breach
properly given by UNIVERSITY. Upon occurrence of a third breach, UNIVERSITY may, at its option, terminate this AGREEMENT upon [**] written notice without an opportunity to cure. 

Section 10.04 Rights after Termination. 
  

	 	(a)	 Upon termination or expiration of this AGREEMENT for any reason, LICENSEE shall: 

 

	 	(i)	 promptly pay all amounts due UNIVERSITY through the effective date of the termination (even if they would
otherwise be payable at a later date, e.g. within [**] after invoicing), including those in Article III (payments) and Section 7.03 (patent expenses); 

  

	 	(ii)	 submit all final reports under Article IV; and 

 

	 	(iii)	 return any CONFIDENTIAL INFORMATION provided to LICENSEE by UNIVERSITY in connection with this AGREEMENT, or,
with UNIVERSITY’s prior approval, destroy such materials, and LICENSEE shall certify in writing that such materials have all been returned or destroyed. 

  
 22 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(b)	 Upon termination of this AGREEMENT for any reason, LICENSEE shall: 

 

	 	(i)	 provide UNIVERSITY a copy of any regulatory data or information filed with any U.S. or foreign government
agency with respect to the LICENSED PRODUCT; and 

  

	 	(ii)	 shall refrain, and shall require its SUBLICENSEES to refrain unless such sublicense is assigned to UNIVERSITY
under Section 10.05, from any further SALES or other commercial exploitation of the LICENSED PRODUCT under this LICENSE AGREEMENT except as provided in Section 10.08. 

Nothing in this section shall be construed as limiting in any way UNIVERSITY’S rights or remedies that UNIVERSITY may otherwise have,
either in law or in equity. 
 Section 10.05 Assignment of Sublicenses. Upon termination of this AGREEMENT, LICENSEE’s interest in
sublicenses granted by it under this AGREEMENT shall at UNIVERSITY’s sole option, terminate or be assigned to UNIVERSITY, including the right to receive income from SUBLICENSEES. LICENSEE shall make provision for UNIVERSITY’s rights under
the preceding sentence to be included in all sublicenses granted by it under this AGREEMENT. 
 Section 10.06 Insolvency. In the event that
LICENSEE (or SUBLICENSEE as applicable) dissolves, liquidates, ceases to carry on business, becomes insolvent, is unable to pay its debts as they become due, makes an assignment for the benefit of creditors, or has a petition for bankruptcy filed
for or against it, this AGREEMENT (or applicable SUBLICENSE) shall automatically terminate. 
 Section 10.07 Survival. Termination or expiration
of this AGREEMENT for any reason shall not release either PARTY from any obligation or liability theretofore accrued prior to such termination or expiration, and LICENSEE shall pay all expenses, costs and attorneys’ fees incurred by UNIVERSITY
in connection with enforcing any obligation or liability of LICENSEE or accrued right of UNIVERSITY. All provisions of this AGREEMENT that would reasonably be expected to survive the termination or expiration of this AGREEMENT shall do so, including
Article III (all--payments), Article VI (all—indemnity, insurance, warranties, damages), Article IX (all--confidentiality), Section 2.04 (reserved rights),
Section 2.05 (license to University), Section 2.08 (governmental rights), , Section 3.07 (challenge to patent rights), Section 4.03 (reporting), Section 4.05 (records), Section 7.02(f) (effect of termination or
expiration on common interest information); Section 10.04 (rights after termination), Section 10.05 (assignment of sublicenses), Section 10.07 (survival), Section 10.08 (inventory), Section 10.09 (ongoing payments), and
Article XI (general—all) survive the termination or expiration of this AGREEMENT. 
 Section 10.08 Inventory. 

  
 23 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

	 	(a)	 Upon termination or expiration of this AGREEMENT, LICENSEE shall provide UNIVERSITY with a written inventory,
including the number of units and anticipated invoice price of all LICENSED PRODUCTS in the possession or under the control of LICENSEE (including any in the process of manufacture). 

 

	 	(b)	 Except with respect to termination for uncured breach by LICENSEE, upon termination of this AGREEMENT, LICENSEE
shall have the privilege of SELLING the inventory of such LICENSED PRODUCTS made or partially made prior to termination within a period of [**] of such termination upon conditions most favorable to UNIVERSITY that LICENSEE can reasonably obtain and
paying any applicable royalties and providing applicable reports associated with such SALES to UNIVERSITY. 

  

	 	(c)	 Upon expiration of this AGREEMENT based on expiration of the PATENT RIGHTS, LICENSEE shall have the privilege
of SELLING the inventory of such LICENSED PRODUCTS made or partially made prior to expiration upon conditions most favorable to UNIVERSITY that LICENSEE can reasonably obtain and paying any applicable royalties and providing applicable reports
associated with such SALES to UNIVERSITY. 

 Section 10.09 Ongoing Payments. Any termination or cancellation under any
provision of this AGREEMENT shall not relieve LICENSEE of its obligation to pay any royalty or other fees due to UNIVERSITY at the time of such termination or cancellation. 

Article XI. GENERAL 
 Section 11.01
Marking. Prior to the issuance of patents under PATENT RIGHTS, LICENSEE agrees to mark LICENSED PRODUCTS (or their containers or labels) SOLD by LICENSEE or SUBLICENSEES under the license granted in this AGREEMENT with the words “Patent
Pending” and following the issuance of one or more patents under PATENT RIGHTS, with the words “Patent No. [**]” or in such a manner as to conform with the patent laws and practice of the country of manufacture, SALE, or importation.

 Section 11.02 Compliance with Laws; Export Controls. LICENSEE agrees to comply with all applicable federal, state, and local laws and
regulations. In particular, LICENSEE shall comply with all applicable U.S. laws dealing with the export and/or management of commodities, technology or information, and that LICENSEE will be responsible for any violation of such by LICENSEE or its
SUBLICENSEES, and that it will defend and hold UNIVERSITY harmless in the event of any legal action of any nature occasioned by such violation. LICENSEE understands that the Arms Export Control Act (AECA), including its implementing International
Traffic In Arms Regulations (ITAR,) and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. LICENSEE
further understands that the U.S. export laws and regulations include (but are not limited to): (a) ITAR and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR
end user-specific requirements; (d) ITAR and EAR end use-specific requirements; (e) Foreign Corrupt Practices Act; and (f) anti-boycott laws and regulations. LICENSEE will comply with all
then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the LICENSED PRODUCTS (including any associated products, items, articles, computer software, media, services,
technical data, and other information). LICENSEE warrants that it will not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed
re-export) the LICENSED PRODUCT (including any associated products, items, articles, computer software, media, services, technical data, and other information) in violation of U.S. export laws and regulations
or other applicable U.S. laws and regulations. LICENSEE will include an appropriate provision in its agreements with its authorized SUBLICENSEES to assure that these parties comply with all then-current applicable U.S. export laws and regulations
and other applicable U.S. laws and regulations. LICENSEE’S OBLIGATIONS TO COMPLY WITH APPLICABLE LAW (INCLUDING U.S. EXPORT CONTROL LAWS AND REGULATIONS) ARE INDEPENDENT OF AND SURVIVE THE TERMINATION OR EXPIRATION OF THIS AGREEMENT. 

  
 24 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 11.03 University Name. LICENSEE agrees not to identify UNIVERSITY in any promotional
advertising or other promotional materials to be disseminated to the public or any portion thereof or to use the name of any UNIVERSITY faculty member, employee, or student or any trademark, service mark, trade name, or symbol of UNIVERSITY, without
UNIVERSITY’S prior written consent. 
 Section 11.04 Press. Notwithstanding Section 11.03, UNIVERSITY may disclose the existence of
this AGREEMENT and non-confidential information regarding the status of LICENSEE’s commercialization of LICENSED PRODUCTS in a press release, on-line, or otherwise,
and on the UNIVERSITY’s website. 
 Section 11.05 Assignment. This AGREEMENT is binding upon and shall inure to the benefit of UNIVERSITY,
its successors and assigns. However, this AGREEMENT shall be personal to LICENSEE, and it is not assignable or transferrable by LICENSEE to any other person or entity without the prior written consent of UNIVERSITY, such consent to be in
UNIVERSITY’s sole discretion. Any purported sale, transfer or assignment without UNIVERSITY’s prior written consent shall be void ab initio, and this AGREEMENT shall immediately terminate. For purposes of this Section, “transfer”
shall include any transfer by operation of law, dissolution, or otherwise (whether voluntary or involuntary). Notwithstanding the foregoing, LICENSEE may assign this AGREEMENT in conjunction with a merger, consolidation or transfer of substantially
all the business to which this AGREEMENT with the prior written consent of UNIVERSITY, such consent not to be unreasonably withheld. 
 Section 11.06
Sponsored Research. If LICENSEE desires UNIVERSITY participation in performing research and development activities directed towards PATENT RIGHTS, negotiation for such assistance shall be separate and apart from this AGREEMENT, and shall be
performed according to UNIVERSITY’S procedures related to research grant and contract activities. 
 Section 11.07 Consulting. In the event
LICENSEE wishes to engage the inventors as consultants, such an arrangement shall be separate and apart from this AGREEMENT, but shall be in keeping with UNIVERSITY’S policy on consulting and ownership of intellectual property developed by
UNIVERSITY employees. 

  
 25 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 11.08 Notices. Any notice or other communication given under this AGREEMENT (except for
correspondence relating to patent preparation, filing, prosecution and/or maintenance matters under Article VII herein) shall be in writing and shall be deemed delivered when sent by certified first class mail, registered mail, or overnight courier,
or by facsimile, provided that a copy of such facsimile is promptly sent by certified first class mail, registered or overnight courier, addressed to the PARTIES as follows (or at such other addresses as the PARTIES may notify each other in
writing): 
 If to UNIVERSITY: 
 Technology Advancement Office

 Mizzou North, Room 706 
 115 Business Loop 70 West 

Columbia, Missouri 65211-8375, USA 
 Attention: Director TAO 

If to LICENSEE: 
 Decibel Therapeutics, Inc. 

1325 Boylston St, Suite 500 
 Boston, MA 02215, USA 

ATTN: VP Legal 
 Section 11.09 No Other Relationship.
In assuming and performing the respective obligations under this AGREEMENT, LICENSEE and UNIVERSITY are each acting as independent parties and neither shall consider itself or represent itself as a joint venture, partner, agent or employee of the
other. 
 Section 11.10 No Waiver. None of the terms, covenants, and conditions of this AGREEMENT can be waived except by the written consent of
the PARTY waiving compliance. A failure by one of the PARTIES to this AGREEMENT to assert its rights for or upon any breach or default of this AGREEMENT shall not be deemed a waiver of such rights nor shall any such waiver be implied from acceptance
of any payment. No such failure or waiver in writing by any one of the PARTIES hereto with respect to any rights, shall extend to or affect any subsequent breach or impair any right consequent thereon. 

Section 11.11 Severability. If any sentence, paragraph, clause or combination of the same is found by a court of competent jurisdiction to be in
violation of any applicable law or regulation, or is unenforceable or void for any reason whatsoever, such sentence, paragraph, clause or combinations of the same shall be severed from the AGREEMENT and the remainder of the AGREEMENT shall remain
binding upon the PARTIES. 
 Section 11.12 Headings. The headings of the paragraphs of this AGREEMENT are inserted for convenience only and
shall not constitute a part hereof. 

  
 26 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.
	  	

 Section 11.13 Choice of Law and Venue. This AGREEMENT shall be construed, interpreted, and
applied in accordance with the laws of the State of Missouri. 
 Section 11.14 Sovereign Immunity. The PARTIES agree that nothing in this
AGREEMENT is intended or shall be construed as a waiver, either express or implied, of any of the immunities, rights, benefits, defenses or protections provided to UNIVERSITY under governmental or sovereign immunity laws from time to time applicable
to UNIVERSITY. 
 Section 11.15 Counterparts. This AGREEMENT may be executed in any number of counterparts, including facsimile or scanned PDF
documents. Each such counterpart, facsimile or scanned PDF document shall be deemed an original instrument, and all of such counterparts, together, shall constitute one and the same executed AGREEMENT 

Section 11.16 Entire Agreement. This AGREEMENT constitutes the entire and only agreement between the PARTIES for PATENT RIGHTS and all other prior
negotiations, representations, agreements, and understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by a written document signed by both PARTIES. 

IN WITNESS WHEREOF, the PARTIES hereto have executed this AGREEMENT by their duly authorized officers or representatives. 

 

									
	 THE CURATORS OF THE
 UNIVERSITY OF
MISSOURI
	 		 	LICENSEE
					
	BY:	 	 /s/ William M. Turpin
	 		 	BY:	  	 /s/ Paula Cobb

			
	NAME: William M. Turpin	 		 	NAME: Paula Cobb
			
	TITLE: Interim Associate Vice Chancellor,	 		 	TITLE: Chief Operating Officer
		 	Economic Development	 		 		  	
					
	DATE	 	 8/26/2019
	 		 	DATE	  	 8/26/2019

  
 27 

 

			
	 [**] UM Patent Commercialization License Exclusive

Decibel Therapeutics, Inc.EX-10.27

 Exhibit 10.27 

CONSULTING AGREEMENT 
 THIS CONSULTING
AGREEMENT (together with its Schedule A, this “Agreement”) made as of February 1, 2020 (the “Effective Date”), is between Decibel Therapeutics, Inc., with a principal business address at 1325
Boylston St., Suite 500, Boston, MA 02215 USA (“Decibel”), and Steven H. Holtzman (“Consultant”). 
  

	1.	 Consulting Services. Whereas Consultant’s last day as an employee of Decibel shall be
January 31, 2019 and Decibel wishes to retain Consultant’s services in an uninterrupted manner, and the parties desire for Consultant’s current equity in Decibel to continue to vest, Decibel hereby retains Consultant to provide
certain consulting services (the “Services”) on the terms described herein. Such Services will include those specific activities described in Schedule A to this Agreement and such other tasks that Decibel reasonably requests
of Consultant during the term of this Agreement. Consultant shall render the Services at such times and locations as Decibel reasonably requests, but Consultant otherwise retains the right to control or direct the details, manner and means by which
Consultant performs the Services. Consultant shall provide Decibel with written project or status reports as Decibel directs, as well as any other writings, specifications, drawings, models, and similar documentation that are appropriate given the
nature of the Services. Consultant shall deliver these reports and other materials to the attention of the Chief Executive Officer of Decibel. Consultant agrees not to employ, subcontract, or otherwise engage any other person or entity to perform
any Services under this Agreement without Decibel’s prior written consent. 

  

	2.	 Compensation.     

 

	 	2.1.	 Fees. Decibel shall pay Consultant a fee for the Services at the rate specified in Schedule A to
this Agreement. Decibel shall pay the applicable fee on a retainer basis, within fifteen (15) days of the start of the relevant quarterly period. Within thirty (30) days of the end of the relevant quarter, Consultant shall provide a
summary detailing the Services performed during the previous quarter and, if applicable, the time spent performing them, as well as all reports or other materials related to the Services. Consultant shall keep reasonably detailed records of all
hours worked on Decibel’s behalf under this Agreement and shall make those records available to Decibel upon Decibel’s reasonable request. Each party represents that, to the best of its knowledge, the fee set forth in Schedule A
constitutes fair market value for the Services. Consultant shall provide said summary of Services to the attention of Accounts Payable for Services rendered hereunder with a copy to the attention of the V.P. Finance. 

 

	 	2.2.	 Expenses. Decibel shall reimburse Consultant for all
pre-approved, reasonable and necessary travel, lodging, and meal expenses required and incurred in performing the Services. These expenses will be reviewed and reimbursed pursuant to Decibel’s corporate
policies for such expenses (that require, among other things, the submission of receipts or other verification). Decibel may provide modest meals to Consultant in the course of Consultant’s performance of the Services. 

 

	3.	 Term. This Agreement will begin on the Effective Date and continue for one (1) year. The Agreement
may be extended by mutual agreement of the parties or earlier terminated in accordance with its terms. Decibel may terminate this Agreement at any time upon ten (10) days prior written notice to Consultant only in the event of (a) a
material breach by Consultant or (b) in the event Decibel ceases to engage in any drug or target discovery related activities. Sections 4 and 5 of this Agreement shall survive any expiration or termination of this Agreement as specified
therein. 

  

	4.	 Confidentiality. The term “Confidential Information” includes all non-public scientific, technical, business or financial information possessed or obtained by, developed for, or given to Decibel that is treated by Decibel as confidential or proprietary, whether or not labeled
“Confidential.” Confidential Information of Decibel includes, without limitation, Deliverables (defined below). During the term of this Agreement and for a period of five (5) 

  
 Decibel Therapeutics, Inc. 

	 	
years thereafter, Consultant will hold Decibel’s Confidential Information in strict confidence; will not disclose such Confidential Information to any third parties; and will not use any
Confidential Information of Decibel for any purpose except as necessary for the performance of the Services. Consultant will have no obligation of confidentiality with respect to any portion of Decibel’s Confidential Information that:

  

	 	a)	 is or later becomes generally available to the public by use, publication or the like, through no fault of
Consultant; 

  

	 	b)	 is obtained without restriction from a third party having the legal right to disclose the same to Consultant;

  

	 	c)	 Consultant already possessed, as evidenced by Consultant’s contemporaneous written records, prior to
receipt thereof from Decibel; or 

  

	 	d)	 is independently developed by Consultant without the use of or access to Decibel’s Confidential
Information, as evidenced by Consultant’s contemporaneous written records. 

 If required to be disclosed by law,
governmental rule or regulation or order of a court with competent jurisdiction, Consultant may disclose the Confidential Information, provided that the disclosure is subject to all applicable governmental or judicial protection available for like
material and reasonable advance notice is given to Decibel. 
  

	5.	 Developments.     

 

	 	5.1.	 Deliverables. Decibel may use any results or products of the Services for any purpose without further
payment or obligation. Consultant shall promptly and fully disclose to Decibel any inventions, improvements, or ideas conceived and/or reduced to practice by Consultant in connection with or during the performance of the Services. All such results,
products, inventions, improvements, or ideas (collectively, “Deliverables”) will be Decibel’s exclusive property. Consultant will provide assistance as needed and without charge (other than reimbursement for actual expenses
incurred) in protecting these Deliverables by patent or otherwise in any and all countries, including in any patent office proceeding or litigation involving these Deliverables. Consultant will keep contemporaneous written records of
Consultant’s work done under this Agreement and will submit these records to Decibel when requested or at the termination of this Agreement. 

  

	 	5.2.	 Works Made For Hire. Any copyrightable work created by Consultant in connection with and arising from
the performance of the Services is a work made for hire, whether published or not. Decibel shall have all rights to and in this work and it shall be Decibel’s property as author and owner of the copyright. Consultant agrees to execute any
documents of assignment that may be required to vest ownership of this copyright in Decibel. Consultant shall not publish on any matter arising from the Services without first obtaining Decibel’s written permission. 

 

	 	5.3.	 Survival. The foregoing provisions will survive any expiration or termination of this Agreement.

  

	6.	 Conflicting Obligations and Debarment. Consultant hereby represents that Consultant:

  

	 	a)	 is presently under no obligation to any other party (including any present or former employer(s), any
government agency, and other parties with whom Consultant consults) that would prevent Consultant from carrying out Consultant’s duties and obligations under this Agreement, or that is inconsistent with this Agreement’s provisions;

  

	 	b)	 has determined that this Agreement complies with the patent, consulting or other policies of Consultant’s
employer; 

  

	 	c)	 has no financial interest in the outcome of the Services; and 

 

	 	d)	 has not been debarred by any relevant governmental or regulatory authority. 

Consultant shall not perform any Services on Decibel’s behalf that would result in any conflict with any third-party obligations, nor
shall Consultant disclose any third-party confidential information to Decibel. If Consultant is or becomes a member of a committee of any entity that sets formularies or develops clinical guidelines during the term of this Agreement or in the two
(2) years thereafter, Consultant will disclose to such committee the existence and nature of the Services contemplated by this Agreement and follow any procedures set forth by such committee relative to the Services. Consultant will not
recruit, entice, induce, or encourage any person to do anything that, if done by Consultant, would violate this Agreement. 

  
 Decibel Therapeutics, Inc. 

	7.	 Independent Contractor. Consultant is an independent contractor and not an employee of Decibel.
Consultant shall not speak for, represent, or obligate Decibel in any way without Decibel’s prior written consent, nor shall Consultant represent him or herself as Decibel’s employee, partner, joint venturer, agent, or officer. Consultant
is not eligible to participate in any benefit plan or program Decibel provides to its employees. Decibel will not make any deductions from its payments to Consultant for income taxes, social security, unemployment insurance, workers’
compensation, or other employment-related taxes, nor will Decibel provide Consultant with insurance coverage for accidents, illnesses, damages or injuries arising out of Consultant’s performance of the Services. Decibel shall not be liable for
any claims arising from any accidents, illnesses, damages, or injuries Consultant may suffer that arise out of Consultant’s performance of the Services. 

  

	8.	 Publicity. Decibel may use Consultant’s name in written materials or oral presentations to current
or prospective customers, investors, or others, provided that these materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to Decibel. 

 

	9.	 Non-Referral. Neither party is under any obligation to solicit,
refer, or solicit referrals of customers or patients for the other party’s business. Neither party will receive any benefit of any kind for making such referrals, nor suffer any detriment for not making them. 

 

	10.	 Breach and Indemnity. Consultant agrees that the compensation and benefits contained in this Agreement
are subject to immediate termination, reduction, or cancellation should Consultant take any action or engage in any conduct that Decibel reasonably considers to be a material violation of this Agreement. Any such termination, reduction, or
cancellation will not prevent Decibel from seeking any other legal or equitable remedies that may be available to Decibel as a result of a violation of this Agreement by Consultant. Consultant agrees to indemnify and hold harmless Decibel from and
against any claims, losses, damages, and expenses (including attorney’s fees) that may arise from the negligence or willful misconduct of Consultant in performing the Services or from any breach of this Agreement by Consultant.

  

	11.	 Notices. Any notice required or permitted under this Agreement must be in writing, delivered personally
or by facsimile, courier, or mail postage prepaid. Such notice shall be addressed to the other party at its address indicated in the letterhead above and shall be effective upon receipt by the addressee. 

 

	12.	 Miscellaneous. This Agreement: 

 

	 	a)	 may not be assigned or otherwise transferred by any party without the consent of the other party;
provided, however, that Decibel may, without such consent, assign its rights and obligations under this Agreement to any affiliate or, in connection with a merger, consolidation or sale of substantially all of the business to which
this Agreement relates, to an unrelated third party; 

  

	 	b)	 is to be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts;

  

	 	c)	 contains the entire agreement between the parties with respect to its subject matter and supersedes all prior
agreements, written or oral, between Decibel and Consultant with respect to its subject matter; 

  

	 	d)	 may not be modified, changed or discharged, in whole or in part, except by an agreement in writing signed by
both parties hereto. 

 No waiver of any term, provision or condition of this Agreement (whether by conduct or otherwise)
in any one or more instances will be deemed to be or construed as a further or continuing waiver of any such term, provision or condition of this Agreement. In the event that any one or more of the provisions contained in this Agreement are, for any
reason, held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in full force and effect. If any
provision of this Agreement is held to be excessively broad, it will be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law. 

  
 Decibel Therapeutics, Inc. 

	13.	 Counterparts and Signatures. This Agreement may be executed in one or more counterparts, each of which
will be deemed an original, and all of which together will be deemed to be one and the same instrument. The parties agree that electronic signatures or signatures affixed to any one of the originals and delivered by facsimile, portable document
format (PDF), or other electronic means shall be valid, binding and enforceable. 

 IN WITNESS WHEREOF, the parties have caused this
Agreement to be executed by their duly authorized representatives as of the Effective Date. 
  

									
	DECIBEL THERAPEUTICS, INC.	 	            	  	STEVEN H. HOLTZMAN
					
	By:	 	 /s/ Laurence Reid
	 		  	By:	 	 /s/ Steven H. Holtzman

	Name:	 	 Laurence Reid
	 		  	Name:	 	 Steven H. Holtzman

	Title:	 	 CEO
	 		  	Title:	 	 Advisor

  
 Decibel Therapeutics, Inc. 

 SCHEDULE A 

Description of Services: 
 As requested by Decibel and as
agreed by Consultant, Consultant will act as a strategic advisor to Decibel management providing consulting services in the areas of management and business development. 

Compensation for the Performance of the Services: 

Consultant will be paid $120,000 on a retainer basis for up to 240 hours of consulting services for the term of this Agreement. Any hours over 240 shall be by
mutual agreement of the parties and shall be paid at the rate of $500/hour. Payments shall be made quarterly, for the forthcoming quarter, per the following schedule: 
  

							
	 Quarter beginning
	  	Payment Amount	 	  	 Date by which payment is to be made

	 February 1, 2020
	  	$	30,000	 	  	 February 15, 2020

	 May 1, 2020
	  	$	30,000	 	  	 May 15, 2020

	 August 1, 2020
	  	$	30,000	 	  	 August 15, 2020

	 November 1, 2020
	  	$	30,000	 	  	 November 15, 2020

  
 Decibel Therapeutics, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]